Good about the pathway AA discussions including for the sickest adults. Randomised double blind trials when the death rate is so high and comparatively survival rates after treatment with remestemcel-L so great, would be unethical.
Good that the FDA is apparently seeing this even if the erstwhile downramper correspondents, cannot.
Good about the pathway AA discussions including for the sickest...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
93.0¢ |
Change
0.015(1.64%) |
Mkt cap ! $1.061B | |||
| Open | High | Low | Value | Volume |
| 92.5¢ | 95.0¢ | 89.0¢ | $7.902M | 8.522M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2945 | 92.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 93.0¢ | 40422 | 4 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
93.0¢ |
Change
0.015 ( 2.54 %) |
||||
| Open | High | Low | Volume | ||
| 92.0¢ | 95.0¢ | 89.5¢ | 2254102 | ||
| Last updated 15.59pm 26/04/2024 ? | |||||
| MSB (ASX) Chart |